Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08RJM
|
|||
| Former ID |
DIB002533
|
|||
| Drug Name |
SD-101
|
|||
| Synonyms |
HCV-ISS; HCV vaccine (ISS), Dynavax/Symphony Dynamo
Click to Show/Hide
|
|||
| Drug Type |
Oligonucleotide
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 3 | [1] | |
| Skin disease [ICD-11: EA00-EM0Z; ICD-10: L00-L99] | Phase 2 | [2] | ||
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1/2 | [3], [4] | ||
| Squamous cell carcinoma [ICD-11: 2B60-2D01] | Phase 1/2 | [3] | ||
| Squamous head and neck cell carcinom [ICD-11: 2D60.0; ICD-10: C77.0] | Phase 1/2 | [5] | ||
| Company |
Scioderm
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02384460) Study of Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | ClinicalTrials.gov (NCT02521870) A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. U.S. National Institutes of Health. | |||
| REF 6 | Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol. 2014 September; 9(9): 811-829. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.